focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Retail Offer

7 Jul 2020 17:46

RNS Number : 3125S
e-Therapeutics plc
07 July 2020
 

EMBARGOED FOR ON 7 JULY 2020.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF E-THERAPEUTICS PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (EACH A "RESTRICTED JURISDICTION").

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRN 779021)

 

7 July 2020

 

e-therapeutics plc

 

("e-therapeutics" or the "Company")

 

Retail Offer

 

e-therapeutics plc (AIM: ETX.L) is pleased to announce a conditional offer for subscription via PrimaryBid (the "Retail Offer") of new ordinary shares of 0.1p each in the Company ("Retail Shares") at an issue price of 12 pence per New Ordinary Share (the "Issue Price"), being a discount of 30.9 per cent to the closing mid-price of 17.4 pence per New Ordinary Share on 6 July 2020, being the latest practicable date prior to the time and date of this announcement.

The Company is also conducting a placing of new Ordinary Shares at the Issue Price by way of a firm placing by Numis Securities Limited (the "Firm Placing"), an associated broker option in the event of additional demand (the "Broker Option"), and direct subscriptions with the Company by individual investors based in various overseas jurisdictions (the "Subscription"), as announced on 7 July 2020.

The PrimaryBid Offer, the Subscription and the Firm Placing are conditional on the new Ordinary Shares to be issued pursuant thereto being admitted to trading on the AIM market of the London Stock Exchange ("Admission"). Admission is expected to be take place at 8.00 a.m. on 15 July 2020. The Retail Offer will not be completed without the Firm Placing also being completed.

The Company will use the funds raised to facilitate a number of initiatives to enable the Company's next stage of growth and value creation by expanding the Company's platform capabilities and asset pipeline.

 

Retail Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the Retail Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play.

The Retail Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors from 4.45 p.m. to 9 p.m. on 7 July 2020. The Retail Offer may close early if it is oversubscribed.

Subscriptions under the Retail Offer will be considered by the Company on a "first come, first served" basis, although preference to be given to the Company's existing shareholders, subject to conditions which are available to view on PrimaryBid.com.

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Retail Offer without giving any reason for such rejection.

No commission is charged to investors on applications to participate in the Retail Offer made through PrimaryBid. It is vital to note that once an application for Retail Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the Retail Offer, visit www.PrimaryBid.com or call PrimaryBid.com on +44 20 3026 4750. 

The Retail Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rank pari passu in all respects with the Company's existing Ordinary Shares.

e-therapeutics plc

Ali Mortazavi, Executive Chairman

Laura Roca-Alonso, Chief Business Officer

 

 

+44 (0)1993 883 125

www.etherapeutics.co.uk

PrimaryBid Limited

Kieran D'Silva / James Deal

+ 44 (0) 203 026 4750

 

 

FTI Consulting

Simon Conway/Stephanie Cuthbert

 

 

 

+44 (0) 203 727 1000

e-therapeutics@fticonsulting.com

Details of the Retail Offer

The Company values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Retail Offer. The Company is therefore offering the Retail Shares through PrimaryBid.com.

The Retail Offer is being made pursuant to an exemption from the requirement to publish a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of a prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority. The Retail Offer is not being made into any Restricted Jurisdiction.

There is a minimum subscription of £100 per investor under the terms of the Retail Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis, although preference will be given to existing shareholders.

For further details please refer to the PrimaryBid.com website at www.PrimaryBid.com. The terms and conditions on which the Retail Offer is made, including the procedure for application and payment for Retail Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for Retail Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for Retail Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the Retail Shares if they are in any doubt. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOERRMFTMTJMBLM
Date   Source Headline
19th Feb 20139:45 amRNSDirector/PDMR Shareholding
15th Feb 20132:27 pmRNSDirector/PDMR Shareholding
14th Feb 20137:00 amRNSDirector/PDMR Shareholding
12th Feb 20134:08 pmRNSDirector/PDMR Shareholding
11th Feb 20133:38 pmRNSDirector/PDMR Shareholding
11th Feb 20137:00 amBUSe-Therapeutics to raise £40 million to advance lead cancer drug and exploit network pharmacology platform
8th Jan 20131:07 pmRNSHolding(s) in Company
18th Dec 20127:00 amBUSClinical Trial Update (ETS2101)
14th Nov 20123:30 pmRNSDirector/PDMR Shareholding
8th Nov 20126:01 pmRNSDirector/PDMR Shareholding
26th Oct 201210:25 amRNSDirector/PDMR Shareholding
23rd Oct 20125:23 pmRNSDirector/PDMR Shareholding
22nd Oct 20127:00 amBUSInterim Results for the six months ended 31 July 2012
2nd Oct 20128:57 amRNSDirector/PDMR Shareholding
25th Sep 20124:19 pmRNSDirector/PDMR Shareholding
12th Sep 20127:00 amBUSe-Therapeutics starts second phase I cancer trial of ETS2101
4th Sep 201211:00 amRNSNotice of Interim Results
6th Aug 20122:25 pmRNSAdditional Listing and Directors' Shareholdings
2nd Aug 20123:35 pmRNSAdditional Listing
31st Jul 20121:06 pmRNSResult of AGM
18th Jul 20125:14 pmRNSHolding(s) in Company
6th Jul 20122:08 pmBUSDirector/PDMR Shareholding
29th Jun 20121:03 pmRNSAnnual Financial Report
19th Jun 20127:00 amBUSe-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer
22nd May 20127:03 amBUSe-Therapeutics' Preliminary Results for the Year Ended 31 January 2012
10th May 20127:00 amRNSNotice of Results
4th May 20126:00 pmRNSDirector/PDMR Shareholding
17th Apr 20123:55 pmRNSChange of Registered Office
29th Mar 20127:00 amBUSPhase I clinical trials of cancer drug ETS2101 approved by regulators
14th Mar 20125:59 pmRNSDirector/PDMR Shareholding
27th Feb 20127:00 amBUSPrime Minister Opens e-Therapeutics' Drug Discovery Centre near Oxford
8th Feb 20122:00 pmBUSe-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference
7th Feb 20128:41 amRNSHolding(s) in Company
6th Feb 20127:00 amBUSDirectorate Change
9th Jan 20122:00 pmBUSe-Therapeutics outlines goals for 2012 and announces presentation at Biotech Showcase Conference
30th Nov 20113:45 pmRNSDirector/PDMR Shareholding
27th Oct 201110:21 amRNSDirector/PDMR Shareholding
19th Oct 20117:00 amRNSInterim Results for the six months to 31 July 2011
26th Sep 20117:00 amRNSPatent for 'Power Behind the Throne'
21st Sep 20119:00 amRNSNotice of Interim Results
12th Sep 20111:06 pmRNSResult of AGM
17th Aug 20114:19 pmRNSDirector/PDMR Shareholding
15th Aug 20112:16 pmRNSDirector/PDMR Shareholding
9th Aug 201112:40 pmRNSDirector/PDMR Shareholding
28th Jul 201110:00 amRNSAnnual Financial Report
28th Jul 20117:30 amRNSDirector/PDMR Shareholding
25th Jul 20117:00 amRNSPreliminary Results and Business Update
29th Jun 20112:38 pmRNSNotice of Results
13th Jun 20117:00 amRNSDirectorate Change
6th Jun 20114:34 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.